Projects per year
Abstract
Introduction: Triple negative breast cancer is defined as a tumor subtype characterized by the lack of expression of hormone receptors for estrogen and progesterone, and human epidermal growth factor receptor 2 (HER2)are considered to be biologically aggressive with higher rates of distant and visceral metastasis. The objective of the study was to describe the outcomes of patients with triple-negative breast cancer according to treatment and stage at the time of diagnosis in the population attended Mederi Hospital. Methodology: Descriptive study of a cohort of women with breast cancer with triple negative subtype attended in the University Hospital Mayor -Mederi between 2014-2018. Results: 28 patients were studied. The proportion of cases for the study population was 7.4% of all cases of breast cancer, the average age was 69 years. 71% were multi-pregnancy and 85% menopausal. 71% had infiltrating tumors and the most frequent clinical stage was IIIB; the outcome of mortality was 7.1% (two cases), and 71% of the patients had a disease-free period as an outcome. Conclusion: Patients diagnosed with triple negative breast cancer from the HUM Mastology Service presented pathological clinical characteristics similar to those reported in the literature, the risk of progression and relapse is given by the type of tumor and tumor infiltration, as well as the complete pathological response
Translated title of the contribution | Clinical outcomes in patients treated for triple negative subtype breast cancer, Hospital Mayor Mederi 2014-2018 |
---|---|
Original language | Spanish |
Publisher | Universidad del Rosario |
State | Published - 29 Jan 2021 |
Externally published | Yes |
Keywords
- breast cancer
- clinical outcomes
- Neoadjuvant
Fingerprint
Dive into the research topics of 'Clinical outcomes in patients treated for triple negative subtype breast cancer, Hospital Mayor Mederi 2014-2018'. Together they form a unique fingerprint.Projects
- 1 Finished
-
Desenlaces clínicos en pacientes tratadas por cáncer de mama subtipo triple negativo, Hospital Mayor Mederi 2014-2018
Vega-Hernandez, P. (PI), De LaPeña, J. ( Academic assessor) & Pedraza, A. M. ( Academic assessor)
22/08/19 → 22/12/20
Project: Research › Clinical Research